Enfusion (NYSE:ENFN) Sets New 52-Week High After Analyst Upgrade

Enfusion, Inc. (NYSE:ENFN)’s share price hit a new 52-week high during mid-day trading on Monday after Piper Sandler raised their price target on the stock from $10.00 to $11.50. Piper Sandler currently has a neutral rating on the stock. Enfusion traded as high as $11.50 and last traded at $11.50, with a volume of 224 shares changing hands. The stock had previously closed at $10.63.

Separately, Stifel Nicolaus lifted their price objective on shares of Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a research note on Wednesday, December 18th. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $10.25.

Insider Activity at Enfusion

In other news, COO Neal Pawar sold 21,801 shares of the firm’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $10.03, for a total transaction of $218,664.03. Following the completion of the transaction, the chief operating officer now directly owns 1,143,544 shares of the company’s stock, valued at approximately $11,469,746.32. This trade represents a 1.87 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 36.44% of the company’s stock.

Institutional Investors Weigh In On Enfusion

Institutional investors and hedge funds have recently made changes to their positions in the company. Arizona State Retirement System bought a new position in Enfusion during the 2nd quarter valued at about $86,000. Harbor Capital Advisors Inc. raised its stake in shares of Enfusion by 12.4% in the third quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company’s stock valued at $113,000 after acquiring an additional 1,315 shares during the last quarter. Belvedere Trading LLC acquired a new position in shares of Enfusion in the 3rd quarter worth approximately $114,000. Paloma Partners Management Co bought a new stake in Enfusion during the 3rd quarter worth approximately $157,000. Finally, The Manufacturers Life Insurance Company increased its holdings in Enfusion by 27.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,562 shares of the company’s stock valued at $167,000 after purchasing an additional 4,239 shares in the last quarter. Institutional investors and hedge funds own 81.05% of the company’s stock.

Enfusion Stock Performance

The company has a 50-day simple moving average of $9.70 and a 200-day simple moving average of $9.00. The stock has a market cap of $1.36 billion, a P/E ratio of 265.32, a P/E/G ratio of 3.98 and a beta of 0.97.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.